Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

1984 - Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC)


30 Sep 2019


Poster Display session 3


Tumour Site

Head and Neck Cancers


Gizem Kaval


Annals of Oncology (2019) 30 (suppl_5): v449-v474. 10.1093/annonc/mdz252


G. Kaval1, M. Altun2, K. Ibis2, K. Ozkaya2, R. Meral2, A.N. Karadeniz2, M. Sarı3, M. Ekenel3, M. Basaran3, S. Bavbek3

Author affiliations

  • 1 Radiation Oncology, Istanbul University Institute of Oncology, 34093 - Istanbul/TR
  • 2 Radiation Oncology, Istanbul University Institute of Oncology, Istanbul/TR
  • 3 Medical Oncology, Istanbul University Institute of Oncology, 34093 - Istanbul/TR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1984


Current treatment of locoregionally advanced NPC (LRA-NPC) is CCRT with or without adjuvant chemotherapy (CT). The value of adding IC to CCRT in LRA-NPC is unclear. We retrospectively evaluated LRA-NPC patients treated with IC followed by CCRT in a single tertiary center in Turkey.


Between 2004 and 2016, 202 patients with nonmetastatic LRA-NPC (stage 3-4), 144 males and 58 females ranging from 17 to 75 (median 49) years old, were treated with IC followed by CCRT. Eleven (%5.4) patients had keratinised (WHO I), and 191 (%94.6) had nonkeratinised or undiffrentiated (WHO II-III) carcinoma. Cumulative radiation dose to primary tumor ranged from 60 to 74 (median 70) Gy. Ninety-one (%45) of the patients received 2-dimensional and 111 (%55) received intensity modulated radiotherapy (IMRT). IC consisted of taxane (T)(75 mg/ m2) and platinum (P)(75 mg/m2) combination (199 patients) or P and fluorouracil or epirubicine (3 patients) combination and 188 of the patients received 3 cycles of IC. Concomittant P was used either weekly (40 mg/m2, 25 patients) or every 3-weekly (100 mg/m2, 177 patients) application. Follow-up ranged from 5 to 167 months (median, 72.5 months).Table: 1143P

Patient and treatment characteristicsn ( % )
III IVA IVB149 (73.7%) 30 (14.9%) 23 (11.4%)
Number of induction courses
2 3 410 (5%) 188 (93.1%) 4 (2%)
Concomittant type
Every 3 weeks (100 mg/m2) Every week (40 mg/m2)177 (87.6%) 25 (12.4%)
RT technique
2-dimensional Intensity modulated91 (45%) 111 (55%)
Radiation dose to primary (Gy)
≤ 70 > 708 (4%) 194 (96%)


Treatment failure was observed in 52 (%25.7) of the patients (21 local, 13 regional and 27 distant). Distant failure rate of all the patients exceeds 13%. Five and 10 years disease free survival (DFS) rates are 75.2% and 70.4% and overall survival (OS) rates are 78.9% and 64% respectively. In univariate analysis patient age favoring those below 49 and stage of disease favoring WHO II-III were all significant predictors of DFS and OS. In addition pathology was a significant predictor of DFS.


LRA-NPC patients treated with IC followed by CCRT have a high locoregional control (LRC) rate. Despite the use of IC distant control remains insufficient and continues to be a challenge in NPC. Besides improving LRC, more effective systemic therapy is needed.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Musa Altun, MD.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.